H Tahara1, H Naito2, K Kise2, T Wakabayashi2, K Kamoi3, K Okihara3, A Yanagisawa4, Y Nakai5, N Nonomura5, E Morii6, T Miki3, N Takakura7. 1. 1] Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan [2] Department of Urology, Kyoto Prefectural University of Medicine, Kamigyou-ku, Kyoto, Japan. 2. Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan. 3. Department of Urology, Kyoto Prefectural University of Medicine, Kamigyou-ku, Kyoto, Japan. 4. Department of Surgical Pathology, Kyoto Prefectural University of Medicine, Kamigyou-ku, Kyoto, Japan. 5. Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. 6. Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. 7. 1] Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan [2] JST, CREST, Sanbancho, Chiyoda-ku, Tokyo, Japan.
Abstract
BACKGROUND: Partner of SLD5 1 (PSF1) is an evolutionarily conserved DNA replication factor. Previous studies have suggested that transcriptional activity of the PSF1 gene correlated with malignancy of cancer cells. The objective of the current study was to evaluate the relationship between PSF1 expression and the clinical features of prostate cancer. METHODS: We determined the expression of PSF1 in 120 needle biopsy samples of prostate cancer by immunohistochemistry. We divided patients into PSF1-positive or -negative groups and analyzed the relationships between the expression of PSF1, the Gleason score, PSA level, TNM classification and prognosis. RESULTS: Our results showed that the PSF1 expression correlated significantly with PSA values at diagnosis (P=0.0028), with tumor grade (P<0.0001), and with clinical stage (P=0.0005). Moreover, the PSF1 expression correlated significantly with overall survival (hazard ratio (HR) 5.5; 95% confidence interval (CI) 2.17-15.8; P=0.003) and progression-free survival in 99 consecutive patients with prostate cancer. Noteworthy, the prognosis of PSF1-positive cases was also worse in patients with a Gleason score of 8-10 (HR 3.7; 95% CI 1.28-13.43; P=0.0143). Limitations include that this study had a retrospective design, that patients in the study were heterogeneous and included those with early and advanced cancer, and that small tumor fragments may not be representative of the entire carcinoma. CONCLUSIONS: PSF1 is expressed in high-grade prostate cancer and may be a useful biomarker to identify patients with a poor prognosis at the time of diagnosis.
BACKGROUND: Partner of SLD5 1 (PSF1) is an evolutionarily conserved DNA replication factor. Previous studies have suggested that transcriptional activity of the PSF1 gene correlated with malignancy of cancer cells. The objective of the current study was to evaluate the relationship between PSF1 expression and the clinical features of prostate cancer. METHODS: We determined the expression of PSF1 in 120 needle biopsy samples of prostate cancer by immunohistochemistry. We divided patients into PSF1-positive or -negative groups and analyzed the relationships between the expression of PSF1, the Gleason score, PSA level, TNM classification and prognosis. RESULTS: Our results showed that the PSF1 expression correlated significantly with PSA values at diagnosis (P=0.0028), with tumor grade (P<0.0001), and with clinical stage (P=0.0005). Moreover, the PSF1 expression correlated significantly with overall survival (hazard ratio (HR) 5.5; 95% confidence interval (CI) 2.17-15.8; P=0.003) and progression-free survival in 99 consecutive patients with prostate cancer. Noteworthy, the prognosis of PSF1-positive cases was also worse in patients with a Gleason score of 8-10 (HR 3.7; 95% CI 1.28-13.43; P=0.0143). Limitations include that this study had a retrospective design, that patients in the study were heterogeneous and included those with early and advanced cancer, and that small tumor fragments may not be representative of the entire carcinoma. CONCLUSIONS:PSF1 is expressed in high-grade prostate cancer and may be a useful biomarker to identify patients with a poor prognosis at the time of diagnosis.
Authors: Agnieszka Gambus; Richard C Jones; Alberto Sanchez-Diaz; Masato Kanemaki; Frederick van Deursen; Ricky D Edmondson; Karim Labib Journal: Nat Cell Biol Date: 2006-03-12 Impact factor: 28.824
Authors: B F Hankey; E J Feuer; L X Clegg; R B Hayes; J M Legler; P C Prorok; L A Ries; R M Merrill; R S Kaplan Journal: J Natl Cancer Inst Date: 1999-06-16 Impact factor: 13.506
Authors: Anthony V D'Amico; Susan Halabi; Robin Vollmer; Marian Loffredo; Elizabeth McMahon; Ben Sanford; Laura Archer; Nicholas J Vogelzang; Eric J Small; Philip W Kantoff Journal: Urology Date: 2008-02-21 Impact factor: 2.649